ENDOLYTIX

Endolytix is developing novel therapeutics to address the most resistant of antibiotic infections that are difficult to access, treat, and patient tolerance for current therapies are low. The lack of susceptibility to antibiotics is in part due to the very thick and complicated cell envelope that prevents effective chemical intervention by blocking access of many drugs from entering mycobacteria. Their defenses go beyond their inhibitory cell envelope but are further reenforced by hiding in macrophage cells designed to kill invading bacteria but are instead usurped into becoming a growth reservoir, thus further making drug access even more challenging... Endolytix Technology, Inc is developing a new therapeutic approach that addresses antibiotic resistance in nontuberculous mycobacterial infections (NTMs) such as the MAC complex and M. abscessus, as well as Mycobacterium tuberculosis. The prevalence of diagnosed NTM infections in the US alone is projected at over 150,000 cases with..

Primary location: Beverly United States